ASG-5ME: Phase I started

Seattle Genetics and Astellas' Agensys Inc. subsidiary began a dose-escalation, U.S. Phase I trial to evaluate ASG-5ME in up to 60 patients. Seattle Genetics and Agensys partnered to develop and comm...